In February, 2017, WHO published its first guidelines on hepatitis B and C testing, aimed at health-care providers and country programme managers, and outlining the public health approach to strengthen and expand testing for hepatitis B virus (HBV) and hepatitis C virus (HCV).
Despite the high global burden of viral hepatitis, and astonishing advances in treatments in recent years, most infected individuals remain unaware of their status. An estimated 110 million people are HCV-antibody positive worldwide (of whom 80 million have active viraemia), and 248 million are estimated to have chronic HBV. However, less than 15% of people with HCV and less than 25% of people with HBV are thought to be aware of their status. Not only does this mean that eligible patients do not receive treatment, but also that patients may present with advanced disease or transmit the infection unknowingly. Identifying individuals for treatment is therefore a priority, particularly in high-risk groups, such as men who have sex with men (MSM) and people who inject drugs (PWID).
Additionally, although most countries report a higher prevalence of HCV among birth cohorts born before blood product screening and infection control procedures were widely implemented, many in these groups do not view themselves as at risk. Indeed, despite the US CDC recommending one-time HCV testing among the baby boomer birth cohort, only 13·8% of this cohort reported ever being tested, according to a 2015 survey, largely due to lack of awareness. The situation is more complex in low-resource settings, where screening efforts are hampered by lack of available data, limited testing facilities, and complex diagnostic algorithms, as well as stigma, particularly among high-risk groups.
Poor implementation and uptake of testing might also hinder progress towards the WHO targets for elimination of viral hepatitis, which include identification of 90% of people with HCV and HBV by 2030. For example, according to a modelling study in this issue of the journal, without expansion of testing programmes, EU countries might run out of patients diagnosed with HCV to treat before 2030 even if universal access to direct-acting antivirals is achieved, pushing these targets frustratingly out of reach.
To efficiently identify those infected, the WHO guidelines recommend general population testing when prevalence is intermediate (≥2%) or high (≥5%), but testing only groups at highest risk of transmission and infection in countries with lower seroprevalence. This includes those with a clinical suspicion of chronic viral hepatitis, health-care workers, and pregnant women; traditional high-risk groups such as MSM, PWID, people with HIV, and prisoners; and sexual partners, family members, and children of those with HBV. Focused testing is also recommended in high-risk birth cohorts.
Enzyme immunoassay testing is recommended in settings where laboratory facilities and trained staff are available, especially where high-throughput testing is needed, but the guidelines recognise that rapid diagnostic tests may be preferable in settings where this is not possible, particularly where rapid testing would facilitate linkage to care. Importantly, any patients with a test result consistent with infection should immediately receive a nucleic acid test to identify active infection, to reassure patients in whom infection has been cleared, and to provide counselling, monitoring, and linkage to treatment for those with viraemic infection. Where possible, testing and counselling services should be integrated into existing health-care facilities, such as HIV and tuberculosis screening services and antenatal clinics.
Sadly, the strength of these recommendations is limited by the lack of studies on HCV and HBV testing. It is clear that research in testing now needs the same impetus that the development of effective treatments has received in the past decade. Crucially, less invasive and simpler methods of sample collection that maintain sufficient diagnostic sensitivity and specificity are needed, as are diagnostic innovations such as rapid point-of-care tests to detect viraemic infection, integrated HIV, HBV, and HCV testing platforms, and effective self-testing measures.
Nevertheless, expansion of testing should not be considered in isolation. Linkage to care is the guiding principle underpinning every successful screening campaign. Governments must be convinced of the benefits of treating early to prevent transmission and disease progression, and expansion of treatment and testing must be coordinated. While treatment access has long been a thorny issue in viral hepatitis, so too will be screening without available treatment and monitoring for patients with a positive test result. Testing is the first and vital step in the care continuum, but it should not and cannot stand alone. ■ The Lancet Gastroenterology & Hepatology 
